Neuropsychopharmacology

• 

  Publication Venue For

  • Slow-release delivery enhances the pharmacological properties of oral 5-hydroxytryptophan: mouse proof-of-concept. 2019
  • Maternal immune activation: reporting guidelines to improve the rigor, reproducibility, and transparency of the model..  44:245-258. 2019
  • Engineered D2R Variants Reveal the Balanced and Biased Contributions of G-Protein and β-Arrestin to Dopamine-Dependent Functions..  43:1164-1173. 2018
  • Parvalbumin Interneurons of the Mouse Nucleus Accumbens are Required For Amphetamine-Induced Locomotor Sensitization and Conditioned Place Preference..  43:953-963. 2018
  • ADHD, Smoking Withdrawal, and Inhibitory Control: Results of a Neuroimaging Study with Methylphenidate Challenge..  43:851-858. 2018
  • Anxiety Associated Increased CpG Methylation in the Promoter of Asb1: A Translational Approach Evidenced by Epidemiological and Clinical Studies and a Murine Model..  43:342-353. 2018
  • 5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice..  42:2163-2177. 2017
  • Opioid Self-Administration is Attenuated by Early-Life Experience and Gene Therapy for Anti-Inflammatory IL-10 in the Nucleus Accumbens of Male Rats..  42:2128-2140. 2017
  • A Primer on Foraging and the Explore/Exploit Trade-Off for Psychiatry Research..  42:1931-1939. 2017
  • Minimum Electric Field Exposure for Seizure Induction with Electroconvulsive Therapy and Magnetic Seizure Therapy..  42:1192-1200. 2017
  • Attenuation of Frontostriatal Connectivity During Reward Processing Predicts Response to Psychotherapy in Major Depressive Disorder..  42:831-843. 2017
  • Coordination of Brain-Wide Activity Dynamics by Dopaminergic Neurons..  42:615-627. 2017
  • A Functional Interleukin-18 Haplotype Predicts Depression and Anxiety through Increased Threat-Related Amygdala Reactivity in Women but Not Men..  42:419-426. 2017
  • Glial and Neuroimmune Mechanisms as Critical Modulators of Drug Use and Abuse..  42:156-177. 2017
  • A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder..  41:2961. 2016
  • Smoking Abstinence-Induced Changes in Resting State Functional Connectivity with Ventral Striatum Predict Lapse During a Quit Attempt..  41:2521-2529. 2016
  • SSRI Augmentation by 5-Hydroxytryptophan Slow Release: Mouse Pharmacodynamic Proof of Concept..  41:2324-2334. 2016
  • Dynamic Resting-State Functional Connectivity in Major Depression..  41:1822-1830. 2016
  • Elucidation of The Behavioral Program and Neuronal Network Encoded by Dorsal Raphe Serotonergic Neurons..  41:1404-1415. 2016
  • Amygdala, Hippocampus, and Ventral Medial Prefrontal Cortex Volumes Differ in Maltreated Youth with and without Chronic Posttraumatic Stress Disorder..  41:791-801. 2016
  • Effects of β-Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behavior in Hypoglutamatergic Mice..  41:704-715. 2016
  • Hippocampal and Insular Response to Smoking-Related Environments: Neuroimaging Evidence for Drug-Context Effects in Nicotine Dependence..  41:877-885. 2016
  • Altered Insula Activity during Visceral Interoception in Weight-Restored Patients with Anorexia Nervosa..  41:521-528. 2016
  • Gene-Stress-Epigenetic Regulation of FKBP5: Clinical and Translational Implications..  41:261-274. 2016
  • Genetic Moderation of Stress Effects on Corticolimbic Circuitry..  41:275-296. 2016
  • Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia..  40:3053-3060. 2015
  • Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults..  40:2745-2752. 2015
  • Relating Intrinsic Low-Frequency BOLD Cortical Oscillations to Cognition in Schizophrenia..  40:2705-2714. 2015
  • Increased Functional Connectivity in an Insula-Based Network is Associated with Improved Smoking Cessation Outcomes..  40:2648-2656. 2015
  • The Psychiatric Genomics Consortium Posttraumatic Stress Disorder Workgroup: Posttraumatic Stress Disorder Enters the Age of Large-Scale Genomic Collaboration..  40:2287-2297. 2015
  • Individualized Low-Amplitude Seizure Therapy: Minimizing Current for Electroconvulsive Therapy and Magnetic Seizure Therapy..  40:2076-2084. 2015
  • A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder..  40:2025-2037. 2015
  • Resting-state connectivity predictors of response to psychotherapy in major depressive disorder..  40:1659-1673. 2015
  • Prediction of smoking cessation with treatment: the emerging contribution of brain imaging research..  40:1309-1310. 2015
  • Sex-specific effects of cigarette mentholation on brain nicotine accumulation and smoking behavior..  40:884-892. 2015
  • Dasotraline for the treatment of attention-deficit/hyperactivity disorder: A randomized, double-blind, placebo-controlled, proof-of-concept trial in adults.  40:2745-2752. 2015
  • Sex-specific effects of cigarette mentholation on brain nicotine accumulation and smoking behavior.  40:884-892. 2015
  • A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression..  39:2867-2873. 2014
  • Nicotine and non-nicotine smoking factors differentially modulate craving, withdrawal and cerebral blood flow as measured with arterial spin labeling..  39:2750-2759. 2014
  • Selective deletion of GRK2 alters psychostimulant-induced behaviors and dopamine neurotransmission..  39:2450-2462. 2014
  • A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia..  39:1568-1577. 2014
  • Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder..  39:1388-1398. 2014
  • Stress-system genes and life stress predict cortisol levels and amygdala and hippocampal volumes in children..  39:1245-1253. 2014
  • Meclizine enhancement of sensorimotor gating in healthy male subjects with high startle responses and low prepulse inhibition.  39:651-659. 2014
  • A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression.  39:2867-2873. 2014
  • A randomized, placebo-controlled study investigating the nicotinic 7 agonist, RG3487, for cognitive deficits in schizophrenia.  39:1568-1577. 2014
  • Altered resting-state functional connectivity of basolateral and centromedial amygdala complexes in posttraumatic stress disorder..  39:351-359. 2014
  • Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder.  39:1388-1398. 2014
  • Nicotine and non-nicotine smoking factors differentially modulate craving, withdrawal and cerebral blood flow as measured with arterial spin labeling.  39:2750-2759. 2014
  • Selective deletion of GRK2 alters psychostimulant-induced behaviors and dopamine neurotransmission.  39:2450-2462. 2014
  • Enhancement of rTMS Neuromodulatory Effects with Novel Waveforms Demonstrated via Controllable Pulse Parameter TMS (cTMS).  38:S246-S247. 2013
  • Optimizing Stimulus Pulse Characteristics for Transcranial Magnetic Stimulation and Electroconvulsive Therapy via Device Development, Computational Modeling, and Biophysically-motivated Dosing Paradigms.  38:S30-S31. 2013
  • The Effects of an Index Course of Magnetic Seizure Therapy and Electroconvulsive Therapy on Verbal Learning and Memory.  38:S426-S427. 2013
  • Nicotine deprivation influences P300 markers of cognitive control..  38:2525-2531. 2013
  • DHEA enhances emotion regulation neurocircuits and modulates memory for emotional stimuli..  38:1798-1807. 2013
  • Treatment for tobacco dependence: effect on brain nicotinic acetylcholine receptor density..  38:1548-1556. 2013
  • Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia..  38:1245-1252. 2013
  • A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia..  38:968-975. 2013
  • A Gαs DREADD mouse for selective modulation of cAMP production in striatopallidal neurons..  38:854-862. 2013
  • DHEA enhances emotion regulation neurocircuits and modulates memory for emotional stimuli.  38:1798-1807. 2013
  • Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia.  38:1245-1252. 2013
  • Treatment for tobacco dependence: Effect on brain nicotinic acetylcholine receptor density.  38:1548-1556. 2013
  • Erratum: Focal electrically administered seizure therapy: A novel form of ECT illustrates the roles of current directionality, polarity, and electrode configuration in seizure induction (Neuropsychopharmacology (2009) 34 (2002-2010) DOI: 10.1038/npp.2009.12).  37:1077. 2012
  • Differential regulation of MeCP2 phosphorylation in the CNS by dopamine and serotonin..  37:321-337. 2012
  • Somatic treatments for mood disorders..  37:102-116. 2012
  • Acute nicotine-induced tachyphylaxis is differentially manifest in the limbic system..  36:2498-2512. 2011
  • Multilocus genetic profile for dopamine signaling predicts ventral striatum reactivity..  36:1940-1947. 2011
  • Child μ-opioid receptor gene variant influences parent-child relations..  36:1165-1170. 2011
  • A dopamine D1 receptor-dependent β-arrestin signaling complex potentially regulates morphine-induced psychomotor activation but not reward in mice..  36:551-558. 2011
  • Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia..  36:616-626. 2011
  • Failures in learning-dependent predictive perception as the key cognitive vulnerability to psychosis in schizophrenia..  36:367-368. 2011
  • Neuroanatomical and neurochemical substrates of timing..  36:3-25. 2011
  • The MATRICS consensus cognitive battery in patients with bipolar i disorder.  36:1587-1592. 2011
  • Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies..  35:1053-1062. 2010
  • Imaging and genetics advances in understanding geriatric depression..  35:349-350. 2010
  • Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder..  34:2489-2496. 2009
  • Clomipramine and glucocorticoid receptor function..  34:2192-2193. 2009
  • Focal electrically administered seizure therapy: a novel form of ECT illustrates the roles of current directionality, polarity, and electrode configuration in seizure induction..  34:2002-2010. 2009
  • Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia..  34:1885-1903. 2009
  • Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial..  34:522-534. 2009
  • Metabolomics: a global biochemical approach to the study of central nervous system diseases..  34:173-186. 2009
  • The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety..  34:6-17. 2009
  • Acute 5-HT reuptake blockade potentiates human amygdala reactivity..  33:3221-3225. 2008
  • Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats..  33:2922-2933. 2008
  • Genetic NMDA receptor deficiency disrupts acute and chronic effects of cocaine but not amphetamine..  33:2701-2714. 2008
  • 'Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation'..  33:2546-2547. 2008
  • N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity..  33:2303-2312. 2008
  • Individual differences in nicotine dependence, withdrawal symptoms, and sex predict transient fMRI-BOLD responses to smoking cues..  33:2148-2157. 2008
  • Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial..  33:1217-1228. 2008
  • ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia..  33:957-970. 2008
  • Estimation of D2-like receptor occupancy by dopamine in the putamen of hemiparkinsonian Monkeys..  33:270-278. 2008
  • Imaging genetics offers new predictive markers of individual differences in behavior and risk for psychiatric diseases.  33:201-202. 2008
  • Gender-specific effects of prenatal and adolescent exposure to tobacco smoke on auditory and visual attention..  32:2453-2464. 2007
  • Regional brain activity correlates of nicotine dependence..  32:2441-2452. 2007
  • Prefrontal white matter lesions and prefrontal task impersistence in depressed and nondepressed elders..  32:2135-2142. 2007
  • Permanent, sex-selective effects of prenatal or adolescent nicotine exposure, separately or sequentially, in rat brain regions: indices of cholinergic and serotonergic synaptic function, cell signaling, and neural cell number and size at 6 months of age..  32:1082-1097. 2007
  • Reversal of cocaine-induced behavioral sensitization and associated phosphorylation of the NR2B and GluR1 subunits of the NMDA and AMPA receptors..  32:377-387. 2007
  • Caspase-3 activation in rat frontal cortex following treatment with typical and atypical antipsychotics..  32:95-102. 2007
  • Is mifepristone useful in psychotic depression?.  31:2793-2794. 2006
  • Effect of antidepressant drugs in mice lacking the norepinephrine transporter..  31:2424-2432. 2006
  • Prenatal nicotine exposure alters the responses to subsequent nicotine administration and withdrawal in adolescence: Serotonin receptors and cell signaling..  31:2462-2475. 2006
  • Erratum: VNS therapy in treatment-resistant depression: Clinical evidence and putative neurobiological mechanisms (Neuropsychopharmacology (2006) 31 (1345-1355) DOI: 10.1038/sj.npp.1301082).  31:2329. 2006
  • Baseline neurocognitive deficits in the CATIE schizophrenia trial..  31:2033-2046. 2006
  • The G72/G30 gene complex and cognitive abnormalities in schizophrenia..  31:2022-2032. 2006
  • Adverse neurodevelopmental effects of dexamethasone modeled in PC12 cells: identifying the critical stages and concentration thresholds for the targeting of cell acquisition, differentiation and viability..  31:1647-1658. 2006
  • Cocaine self-administration reduces excitatory responses in the mouse nucleus accumbens shell..  31:1444-1451. 2006
  • Lobar distribution of lesion volumes in late-life depression: the Biomedical Informatics Research Network (BIRN)..  31:1500-1507. 2006
  • VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms..  31:1345-1355. 2006
  • Visuospatial memory deficits emerging during nicotine withdrawal in adolescents with prenatal exposure to active maternal smoking..  31:1550-1561. 2006
  • Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics..  31:1249-1263. 2006
  • Sex differences in neurochemical effects of dopaminergic drugs in rat striatum..  31:1193-1202. 2006
  • Critical prenatal and postnatal periods for persistent effects of dexamethasone on serotonergic and dopaminergic systems..  31:904-911. 2006
  • Henri Begleiter, 1935-2006..  31:1840-. 2006
  • Increased pituitary volume in ...psychosis study..  31:243. 2006
  • Lasting effects of developmental dexamethasone treatment on neural cell number and size, synaptic activity, and cell signaling: critical periods of vulnerability, dose-effect relationships, regional targets, and sex selectivity..  31:12-35. 2006
  • Cortical white matter microstructural abnormalities in bipolar disorder..  30:2225-2229. 2005
  • Abstinence-induced changes in self-report craving correlate with event-related FMRI responses to smoking cues..  30:1940-1947. 2005
  • Disruption of rat forebrain development by glucocorticoids: critical perinatal periods for effects on neural cell acquisition and on cell signaling cascades mediating noradrenergic and cholinergic neurotransmitter/neurotrophic responses..  30:1841-1855. 2005
  • Novelty seeking and stereotypic activation of behavior in mice with disruption of the Dat1 gene..  30:1818-1831. 2005
  • Trauma, proximity, and developmental psychopathology: the effects of war and terrorism on children..  30:1781-1792. 2005
  • Erratum: Novelty seeking and stereotypic activation of behavior in mice with disruption of the DatI gene (Neuropsychopharmacology (April 27, 2005), DOI:10.1038/sj.npp.1300724).  30:1772. 2005
  • Gestational dexamethasone treatment elicits sex-dependent alterations in locomotor activity, reward-based memory and hippocampal cholinergic function in adolescent and adult rats..  30:1617-1623. 2005
  • Glutamatergic dysfunction in OCD..  30:1735-1740. 2005
  • Reversal of clozapine effects on working memory in rats with fimbria-fornix lesions..  30:1121-1127. 2005
  • Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy..  30:445-460. 2005
  • Medical comorbidity in a bipolar outpatient clinical population..  30:401-404. 2005
  • Effects of prenatal nicotine exposure on primate brain development and attempted amelioration with supplemental choline or vitamin C: neurotransmitter receptors, cell signaling and cell development biomarkers in fetal brain regions of rhesus monkeys..  30:129-144. 2005
  • Nicotine therapy in adulthood reverses the synaptic and behavioral deficits elicited by prenatal exposure to phenobarbital..  30:156-165. 2005
  • Regional heterogeneity for the intracranial self-administration of ethanol and acetaldehyde within the ventral tegmental area of alcohol-preferring (P) rats: Involvement of dopamine and serotonin.  30:330-338. 2005
  • Serotonergic cell signaling in an animal model of aging and depression: olfactory bulbectomy elicits different adaptations in brain regions of young adult vs aging rats..  30:52-57. 2005
  • A systematic review of antidepressant placebo-controlled trials for geriatric depression: limitations of current data and directions for the future..  29:2285-2299. 2004
  • Is there a definition of remission in late-life depression that predicts later relapse?.  29:2272-2277. 2004
  • Prefrontal neuropsychological predictors of treatment remission in late-life depression..  29:2266-2271. 2004
  • Does prenatal nicotine exposure sensitize the brain to nicotine-induced neurotoxicity in adolescence?.  29:1440-1450. 2004
  • Prenatal nicotine exposure alters the response to nicotine administration in adolescence: effects on cholinergic systems during exposure and withdrawal..  29:879-890. 2004
  • The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice..  29:221-228. 2004
  • Left orbital frontal cortex volume and performance on the benton visual retention test in older depressives and controls..  28:2179-2183. 2003
  • Magnetic seizure therapy improves mood in refractory major depression..  28:2045-2048. 2003
  • Short-term adolescent nicotine exposure has immediate and persistent effects on cholinergic systems: critical periods, patterns of exposure, dose thresholds..  28:1935-1949. 2003
  • Safety and feasibility of magnetic seizure therapy (MST) in major depression: randomized within-subject comparison with electroconvulsive therapy..  28:1852-1865. 2003
  • Serotonin-related gene polymorphisms and central nervous system serotonin function..  28:533-541. 2003
  • Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents..  28:1-13. 2003
  • Dextroamphetamine modulates the response of the human amygdala..  27:1036-1040. 2002
  • Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia..  27:684-686. 2002
  • Nicotine interactions with haloperidol, clozapine and risperidone and working memory function in rats..  27:534-541. 2002
  • Stress invalidates reported effects of sodium valproate on brain CRF systems..  26:411-414. 2002
  • Effects of the selective norepinephrine reuptake inhibitor reboxetine on norepinephrine and serotonin transmission in the rat hippocampus..  25:845-857. 2001
  • Subtypes of mania determined by grade of membership analysis..  25:373-383. 2001
  • Serum melanotransferrin, p97 as a biochemical marker of Alzheimer's disease..  25:84-90. 2001
  • Sex differences in cocaine-stimulated motor behavior: disparate effects of gonadectomy..  25:118-130. 2001
  • Increased tonic activation of rat forebrain 5-HT(1A) receptors by lithium addition to antidepressant treatments..  22:346-356. 2000
  • Alterations in baseline activity and quinpirole sensitivity in putative dopamine neurons in the substantia nigra and ventral tegmental area after withdrawal from cocaine pretreatment..  18:222-232. 1998
  • Gender difference in cocaine-induced HPA axis activation..  16:399-407. 1997
  • Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia..  15:587-594. 1996
  • Nicotine-haloperidol interactions and cognitive performance in schizophrenics..  15:429-436. 1996
  • Benzodiazepine receptor ligands with different intrinsic efficacies alter ethanol intake in alcohol-nonpreferring (NP) rats.  14:55-66. 1996
  • CATECHOLAMINE RECEPTORS - MOLECULAR CHARACTERIZATION AND PHYSIOLOGICAL IMPLICATIONS.  9:S35-S36. 1993
  • Cellular regulation of the benzodiazepine/GABA receptor: arachidonic acid, calcium, and cerebral ischemia..  6:119-125. 1992
  • Alterations in the hypothalamic-pituitary-adrenal axis in a proposed animal model of depression with genetic muscarinic supersensitivity..  4:87-93. 1991
  • Effects of propranolol on cardiovascular and neuroendocrine responses to mental arithmetic in type A men..  1:337-340. 1988
  • Aging- and Stress-Related Epigenetic Disinhibition of FKBP5 Contributes to NF-KB-Driven Inflammation and Cardiovascular Risk 2017
  • Increased Activation in Precuneus and Parahippocampus When Smokers View Tobacco Retail Outlets: Results of a GPS plus fMRI 'Community Neuroscience' Study 2017
  • Meta-Analysis of DNA Methylation and PTSD in the Psychiatric Genomics Consortium PTSD Epigenetics Workgroup 2017
  • Phase I Open Label Trial of Autologous Cord Blood for Treatment of Autism: Correlations Between Behavioral Improvement and Increased White Matter Connectivity in Children With Autism 2017
  • fMRI- and Computationally-Guided rTMS Enhances Performance in Working Memory Manipulation 2017
  • Comparing the Effects of an Index Course of Magnetic Seizure Therapy and Electroconvulsive Therapy on Quality of Life 2015
  • From Good Habit to Bad: Corticostriatal Synaptic and Circuit Mechanisms in Habit and Compulsion 2015
  • Posttraumatic Stress Disorder and Common Genetic Variants Affect Subcortical Brain Volumes in Recent Military Veterans 2015
  • A Pharmacogenetics Supported Clinical Trial to Delay Onset of Mild Cognitive Impairment due to Alzheimer's Disease Using Low Dose Pioglitazone: The Tommorrow Study 2014
  • Neuroserpin Protects Parvalbumin Interneurons Against Perineuronal Net Degradation for Cortical Stability 2014
  • The Influence of APOE Genotype on Aging's Effect on Brain Structure and Cognition in Younger Adults with and without Depression 2014
  • Neurosteroids as Novel Therapeutics and Biomarker Candidates in Schizophrenia and PTSD 2013
  • A preliminary metabolomic analysis of older adults with and without depression 2006
  • Bupropion reinstates cocaine seeking behavior in rats 2006
  • Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: Candidate mechanism for superior efficacy? 2006
  • Decisional competence to complete psychiatric advance directives 2006
  • Effects of 24 hour smoking abstinence on sustained and event-related brain activity during continuous working memory: Preliminary results of an fMRI study 2006
  • Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial 2006
  • Pregnenolone alterations in parietat cortex are associated with death by suicide in patients with schizophrenia 2006
  • Sodium oxybate for the treatment of fibromyalgia: A double-blind, placebo-controlled trial 2006
  • Transcranial magnetic stimulation: Effectiveness and safety in a randomized, controlled, multisite clinical trial and an open-label extension study 2006
  • cTMS: A novel TMS device inducing near rectangular pulses with controllable pulse width 2006
  • 5HTTLPR genotypes and environmental stress interact to affect sleep quality 2005
  • A randomized, double-blind, placebo-controlled, flexible-dose, trial of augmentation with oros methylphenidate in treatment resistant depression 2005
  • Candidate gene polymorphisms and birth weight (BW) in the national longitudinal study of adolescent health (add health) 2005
  • Clozapine effects on memory function are reversed by hippocampal damage 2005
  • Deficit in the GABAergic neuroactive steroid allopregnanolone in Alzheimer's dementia and relevance to neuropathological disease stage: Investigations in temporal cortex 2005
  • Serotonin transporter polymorphism influences the prolactin response to tryptophan and stress 2005
  • Neuroactive steroid alterations in schizophrenia and bipolar disorder: A negative ion chemical ionization gas chromatography/mass spectrometry investigation in posterior cingulate 2004
  • Neuroactive steroids in Alzheimer's disease: Investigations in prefrontal cortex 2004
  • Plasma amyloid beta 1-42 levels in geriatric depression: A pilot study 2004
  • The neuroactive steroid dehydroepiandrosterone sulfate (DHEAS) predicts nicotine dependence severity 2004